In last trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 3.01 million shares changing hands with its beta currently measuring 0.78. Company’s recent per share price level of $1.47 trading at $0.01 or 0.68% at ring of the bell on the day assigns it a market valuation of $308.11M. That closing price of AKBA’s stock is at a discount of -68.71% from its 52-week high price of $2.48 and is indicating a premium of 46.94% from its 52-week low price of $0.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.09 million shares which gives us an average trading volume of 3.25 million if we extend that period to 3-months.
For Akebia Therapeutics Inc. (AKBA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Upright in the green during last session for gaining 0.68%, in the last five days AKBA remained trading in the green while hitting it’s week-highest on Wednesday, 07/24/24 when the stock touched $1.47 price level, adding 6.29% to its value on the day. Akebia Therapeutics Inc.’s shares saw a change of 18.55% in year-to-date performance and have moved 4.26% in past 5-day. Akebia Therapeutics Inc. (NASDAQ:AKBA) showed a performance of 62.66% in past 30-days. Number of shares sold short was 13.11 million shares which calculate 3.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a rise of 77.38% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -308.16% in reaching the projected high whereas dropping to the targeted low would mean a loss of -308.16% for stock’s current value.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Statistics highlight that Akebia Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 5.00% of value to its shares in past 6 months, showing an annual growth rate of 0.00% while that of industry is 13.30.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.46% during past 5 years.
AKBA Dividends
Akebia Therapeutics Inc. is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Akebia Therapeutics Inc. (NASDAQ:AKBA)’s Major holders
Insiders are in possession of 2.14% of company’s total shares while institution are holding 27.05 percent of that, with stock having share float percentage of 27.64%. Investors also watch the number of corporate investors in a company very closely, which is 27.05% institutions for Akebia Therapeutics Inc. that are currently holding shares of the company. ALERCE INVESTMENT MANAGEMENT, L.P. is the top institutional holder at AKBA for having 13.21 million shares of worth $24.17 million. And as of 2024-03-31, it was holding 6.9536 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 8.23 million shares on 2024-03-31. The number of shares represents firm’s hold over 4.3317 of outstanding shares, having a total worth of $15.05 million.
